Mon, Dec 29, 2014, 9:38 AM EST - U.S. Markets close in 6 hrs 22 mins


% | $
Quotes you view appear here for quick access.

Netflix, Inc. (NFLX) Message Board

lukb4ujump 251 posts  |  Last Activity: Dec 26, 2014 2:23 PM Member since: Aug 10, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • to the drug, lose weight and change their lives. So 83% of the 100,000,000 obese will respond to Belviq or Bel Phen. The weight loss is enough to change their lives forever.

    Why would you bashers and shorts want to make money destroying a company that will do so much good. Saving lives and medical expenses? Seems there are better places to try and make money.

  • over 5 months ahead of schedule and ahead of guidance. How about giving them a thumbs up for blowing out that guidance over and over. Insurance coverage will be closer to 80% by their 70% deadline maybe even higher...

    Or, you can keep posting FUD and personal attacks on Arena management.

    Make it a great day.

  • in how they are going to address this next weight loss season. Don't focus on Arena or their management, they have nothing to do with marketing Belviq.

  • " we have stated that we would have the data available by the end of this calendar year"......" expect is sooner rather then later"........ "the best place to release it is,,,,, but with so much data that has to be accumulated and processed we might not get it done in time"....

    Just some excerpts from a conversation.

  • women's magazines. They were selling a new and healthy weight loss supplement. The amino acid was acclaimed and a easier and healthier way to lose weight. They even went so far as to compare themselves to BELVIQ, saying that they are more effective then the newest and hottest weight loss drug.

    Also we now have 2 companies that have tried to sell fake/counterfeit Belviq out of China

    What is the point you ask?

    Obviously those trying to capitalize on this market have done their research and know that Belviq is a winner and is going to continue to grow... Slowly and surely will win this race.

    PSCM is buying....

  • dollar market cap price target they show their true colors. They don't want a drug that will cure the cause, they want a drug that will treat the symptoms year after year after year. I don't believe in conspiracy but I do believe in following the money. IF Belviq were successful at helping 20 million people go from obese to healthy, how many companies would see their revenue drop significantly? Insulin companies, Mc Donalds, all those companies that have helped the obese become obese and those that want to treat the symptoms for years to come.

    That is why we get no love, it is a destructive technology when you look at the big picture...

    These analysts actually gave the company a price target that high after Phase II studies, ICPT has a long way to go to get approval and that drug only treats the symptom... Belviq helps them lose the weight and heal naturally..

  • lukb4ujump lukb4ujump Dec 4, 2014 4:03 PM Flag

    So selling at an annualized rate of 780,000 scripts per year and gross revenue before discounts and rebates of 156 million a year after only being on the market for 15 months is what you call rotten sales?

    This is a new and novel drug in a tainted and jaded market I think they are doing just fine. And as word continues to spread about the health benefits and the success of those on the drug spread it will only get better.

    Thanks for playing now back on ignore for you.

  • lukb4ujump lukb4ujump Nov 3, 2014 9:59 AM Flag

    When the doctors scripting the 150,000 scripts per week get this safety data and efficacy results what do you think is going to happen?

    If you say nothing, they will not add Belviq to some of their patients treatment protocol you are not being honest with yourself.

  • lukb4ujump lukb4ujump Dec 1, 2014 7:48 PM Flag

    I have been here a very long time and have given insight to conversations that have taken place. Getting info in advance of it hitting the airways.

    So, just like my contact stated to expect results sooner rather then later, later being the end of the year around Bel Phen study we are going to see a new push for this next weight loss season.

  • Reply to

    IMS week ended 10/3/2014

    by sharonconk Oct 10, 2014 10:05 AM
    lukb4ujump lukb4ujump Oct 10, 2014 10:45 AM Flag

    She is posting facts and numbers on the script data that is not a criminal enterprise.

    How was that compared to the overall market, we should have increased market share again by a lot.

  • Reply to

    Will it ever have another up day????

    by just4tsd Nov 25, 2014 11:07 AM
    lukb4ujump lukb4ujump Nov 25, 2014 12:40 PM Flag

    This is one of those investments that will get unfairly hammered until the very last minute. Then it will finally move up. The game plan is to destroy the retail investor psyche, make them just give up and walk away. The good news is that the drug is doing well and the GPCR technology works. Don't play options and don't use margin. The key here is waiting for Belviq to become a household name. It took what 3 years to take Aricept and that market from a 100 million a year market to multi billions per year in sales. Same strategy, educate the doctors and get them in your side.

  • Reply to

    Jack is not an effective CEO

    by eanthony_1961 Nov 4, 2014 5:44 PM
    lukb4ujump lukb4ujump Nov 4, 2014 6:03 PM Flag

    I likes how the commentator teed up the question for him to knock it out of the park. Bio Tech companies are priced based on their potential market and future. Your price has gone from 11 to 4 bucks a share why is Wall Street not pricing in the enormous market potential of your drug. ( paraphrased )....


    Tweeeet Tweeeeet Strike 3 !!!!!! There is no excuse for not knowing your drug and the market stats enough to be able to have 5 canned answers that are within your attorneys guidelines to address most questions in a positive and exciting way. To get people excited about the size of the market, the potential of the market. We have 100,000,000 obese in America and 42 million adult smokers. If we just get 1 million from each group to take Belviq that is 24,000,000 scripts per year. and that is only 1% of the obese market and 3% of the smoking market. These numbers tell me that Wall Street is not paying attention to what the real potential is..

  • lukb4ujump lukb4ujump Nov 18, 2014 12:02 PM Flag

    Nope go back and listen to their CC, the 70% deadline was tied to their year end not calendar year end. Their fiscal ends March 2015...

    That was my point Arena has nothing to do with marketing.. Sitting here bashing management over sales and marketing results is pointless. Arena has only one thing to do these days. Make Belviq, and expand the pipeline and other Belviq indications... They have no marketing responsibility and any success for increase in sales and market penetration is all on Eisai.

  • Reply to

    Think really hard-

    by peter_north444 Dec 23, 2014 3:00 PM
    lukb4ujump lukb4ujump Dec 23, 2014 3:47 PM Flag

    DNDN's drug Provenge, was very expensive at almost 100k for 3 treatments and a few more months of life...... So I don't think you can compare the two drugs or the markets.

    Getting doctors off of the diet and exercise mantra after all of the failed dangerous drugs that were put on the markets over the last 15 years is no small task. But we now have over 90k doctors that have scripted the drug. We are gaining traction in the medical community and that is a great base to build upon.

    This will take time and I agree with the posters sentiment. We can't stop the manipulation, the fomenting or the hedge funds from playing their games with the stock. So know what you own and don't use margin or options...

  • Reply to

    10% Thresh hold

    by mistarichter Oct 13, 2014 10:48 AM
    lukb4ujump lukb4ujump Oct 13, 2014 10:56 AM Flag

    I am sure they got some longs to sell at this point. I agree we have nothing in reality happening that warrants this kind of sell off the last few weeks. We are executing and that is the key. Scripts are growing, we are gaining market share, the market for people taking weight loss drugs is growing, studies are completed and data is getting analyzed. We are moving the pipeline forward and before the end of the year we should see the Bel PHen study data and the Belviq for smoking study data. Unofficial results are very positive. Insurance coverage is growing which should get more people reordering Belviq.

    These sanctioned bear raids unfortunately are part of the markets these days. We just have to learn to live with them.

  • lukb4ujump lukb4ujump Nov 17, 2014 5:22 PM Flag

    Went on a cruise and was gone for 10 days. Wife said no internet, no phones, NO BUSINESS. Happy wife, happy life.

  • do was slight the data and ask why other studies were not done. He pointed out Chantix Phase IiI results... Lets see who spins this on blogs and fake investment coverage....

  • Reply to

    Regarding Bel Phen results.

    by lukb4ujump Oct 7, 2014 12:03 PM
    lukb4ujump lukb4ujump Oct 7, 2014 12:15 PM Flag

    They promised by the end of this calendar year they will make that deadline and it will come in on time.

  • Reply to

    pfizer, game over for shorts

    by awsgv Oct 8, 2014 1:52 PM
    lukb4ujump lukb4ujump Oct 8, 2014 2:04 PM Flag

    Game for shorts is long from over, they are a constant part of the markets and an integral part of "price discovery" ;-)

  • lukb4ujump lukb4ujump Oct 24, 2014 10:59 AM Flag

    Did you see this? I just noticed this.
    Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

    This study has been completed.

335.34-4.71(-1.39%)9:38 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.